Drugs / MG-1
last change Dec 2014 re-read 2 minutes ago

MG-1

Developed for
alcoholic fatty liver disease · alcoholic hepatitis
Investigated by
PharmaKing

Trials 1 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02019056 Nov 2010 → Dec 2014 alcoholic fatty liver disease, alcoholic hepatitis PharmaKing Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MG-1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02019056